Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes : a review of clinical trials. / Madsbad, Sten; Krarup, Thure; Deacon, Carolyn F; Holst, Jens Juul.

In: Current Opinion in Clinical Nutrition and Metabolic Care, Vol. 11, No. 4, 07.2008, p. 491-9.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Madsbad, S, Krarup, T, Deacon, CF & Holst, JJ 2008, 'Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials', Current Opinion in Clinical Nutrition and Metabolic Care, vol. 11, no. 4, pp. 491-9. https://doi.org/10.1097/MCO.0b013e328302f414

APA

Madsbad, S., Krarup, T., Deacon, C. F., & Holst, J. J. (2008). Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Current Opinion in Clinical Nutrition and Metabolic Care, 11(4), 491-9. https://doi.org/10.1097/MCO.0b013e328302f414

Vancouver

Madsbad S, Krarup T, Deacon CF, Holst JJ. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Current Opinion in Clinical Nutrition and Metabolic Care. 2008 Jul;11(4):491-9. https://doi.org/10.1097/MCO.0b013e328302f414

Author

Madsbad, Sten ; Krarup, Thure ; Deacon, Carolyn F ; Holst, Jens Juul. / Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes : a review of clinical trials. In: Current Opinion in Clinical Nutrition and Metabolic Care. 2008 ; Vol. 11, No. 4. pp. 491-9.

Bibtex

@article{c2a7f8177ae54244b151751aa6ce2b76,
title = "Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials",
abstract = "PURPOSE OF REVIEW: To discuss the virtues and shortcomings of the glucagon-like peptide-1 receptor agonists and the dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes.RECENT FINDINGS: The injectable glucagon-like peptide-1 receptor agonists exenatide significantly improves glycaemic control, with average reductions in haemoglobin A1c of about 1.0{\%}, fasting plasma glucose of about 1.4 mmol/l, and causes a weight loss of approximately 2-3 kg after 30 weeks of treatment in patients with type 2 diabetes. The adverse effects are transient nausea and vomiting. The long-acting glucagon-like peptide-1 receptor agonists liraglutide and exenatide long-acting release reduce haemoglobin A1c by about 1.0-2.0{\%} and have fewer gastrointestinal side-effects. The orally available dipeptidyl peptidase-4 inhibitors, that is sitagliptin and vildagliptin reduce haemoglobin A1c by 0.5-1.0{\%}, are weight neutral and without gastrointestinal side-effects.SUMMARY: The benefits and position of the glucagon-like peptide-1 analogues and the dipeptidyl peptidase-4 inhibitors in the diabetes treatment algorithm will be clarified when we have long-term trials with hard cardiovascular endpoints and data illustrating the effects on the progression of type 2 diabetes.",
keywords = "Adamantane, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Dipeptidyl Peptidase 4, Dipeptidyl-Peptidase IV Inhibitors, Glucagon-Like Peptide 1, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Nitriles, Peptides, Pyrazines, Pyrrolidines, Receptors, Glucagon, Triazoles, Venoms",
author = "Sten Madsbad and Thure Krarup and Deacon, {Carolyn F} and Holst, {Jens Juul}",
year = "2008",
month = "7",
doi = "10.1097/MCO.0b013e328302f414",
language = "English",
volume = "11",
pages = "491--9",
journal = "Current Opinion in Clinical Nutrition and Metabolic Care",
issn = "1363-1950",
publisher = "Lippincott Williams & Wilkins",
number = "4",

}

RIS

TY - JOUR

T1 - Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes

T2 - a review of clinical trials

AU - Madsbad, Sten

AU - Krarup, Thure

AU - Deacon, Carolyn F

AU - Holst, Jens Juul

PY - 2008/7

Y1 - 2008/7

N2 - PURPOSE OF REVIEW: To discuss the virtues and shortcomings of the glucagon-like peptide-1 receptor agonists and the dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes.RECENT FINDINGS: The injectable glucagon-like peptide-1 receptor agonists exenatide significantly improves glycaemic control, with average reductions in haemoglobin A1c of about 1.0%, fasting plasma glucose of about 1.4 mmol/l, and causes a weight loss of approximately 2-3 kg after 30 weeks of treatment in patients with type 2 diabetes. The adverse effects are transient nausea and vomiting. The long-acting glucagon-like peptide-1 receptor agonists liraglutide and exenatide long-acting release reduce haemoglobin A1c by about 1.0-2.0% and have fewer gastrointestinal side-effects. The orally available dipeptidyl peptidase-4 inhibitors, that is sitagliptin and vildagliptin reduce haemoglobin A1c by 0.5-1.0%, are weight neutral and without gastrointestinal side-effects.SUMMARY: The benefits and position of the glucagon-like peptide-1 analogues and the dipeptidyl peptidase-4 inhibitors in the diabetes treatment algorithm will be clarified when we have long-term trials with hard cardiovascular endpoints and data illustrating the effects on the progression of type 2 diabetes.

AB - PURPOSE OF REVIEW: To discuss the virtues and shortcomings of the glucagon-like peptide-1 receptor agonists and the dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes.RECENT FINDINGS: The injectable glucagon-like peptide-1 receptor agonists exenatide significantly improves glycaemic control, with average reductions in haemoglobin A1c of about 1.0%, fasting plasma glucose of about 1.4 mmol/l, and causes a weight loss of approximately 2-3 kg after 30 weeks of treatment in patients with type 2 diabetes. The adverse effects are transient nausea and vomiting. The long-acting glucagon-like peptide-1 receptor agonists liraglutide and exenatide long-acting release reduce haemoglobin A1c by about 1.0-2.0% and have fewer gastrointestinal side-effects. The orally available dipeptidyl peptidase-4 inhibitors, that is sitagliptin and vildagliptin reduce haemoglobin A1c by 0.5-1.0%, are weight neutral and without gastrointestinal side-effects.SUMMARY: The benefits and position of the glucagon-like peptide-1 analogues and the dipeptidyl peptidase-4 inhibitors in the diabetes treatment algorithm will be clarified when we have long-term trials with hard cardiovascular endpoints and data illustrating the effects on the progression of type 2 diabetes.

KW - Adamantane

KW - Clinical Trials as Topic

KW - Diabetes Mellitus, Type 2

KW - Dipeptidyl Peptidase 4

KW - Dipeptidyl-Peptidase IV Inhibitors

KW - Glucagon-Like Peptide 1

KW - Glucagon-Like Peptides

KW - Humans

KW - Hypoglycemic Agents

KW - Nitriles

KW - Peptides

KW - Pyrazines

KW - Pyrrolidines

KW - Receptors, Glucagon

KW - Triazoles

KW - Venoms

U2 - 10.1097/MCO.0b013e328302f414

DO - 10.1097/MCO.0b013e328302f414

M3 - Journal article

C2 - 18542012

VL - 11

SP - 491

EP - 499

JO - Current Opinion in Clinical Nutrition and Metabolic Care

JF - Current Opinion in Clinical Nutrition and Metabolic Care

SN - 1363-1950

IS - 4

ER -

ID: 132048974